Why the study?
Antineoplastic drug cardiotoxicity alters long-term cancer survivor outcomes, making its recognition and management essential for general internists and cardiologists.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Cardio-oncology integration may improve surveillance in cancer survivors; leaves open optimal prevention strategies from Level 5 data.
Cardiomyopathy is an adverse outcome of antineoplastic drug therapy that has become increasingly relevant in the management of cancer survivors.As the efficacy of anticancer treatments has improved,long-term outcomes are altered by the development of cardiotoxicity, which may be associated with an even worse prognosis than that of the underlying malignancy.From the research into mechanisms,prevention,and treatment,the specialized field of cardio-oncology has evolved, but the recognition and appropriate management of these patients is important for the general internist and general cardiologist as well.
No takes yet. Share an insight, caveat, or question.
Hernán et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: